H20.823 Vogt-Koyanagi syndrome, bilateral

Name of the Condition

• Vogt-Koyanagi syndrome, bilateral

Summary

Vogt-Koyanagi syndrome is a rare, multisystem inflammatory disorder primarily affecting the eyes, skin, and central nervous system. This specific code denotes bilateral involvement of the eyes. The condition is characterized by uveitis (inflammation of the uveal tract), often accompanied by extraocular manifestations such as vitiligo, poliosis (whitening of hair), and auditory disturbances. It typically follows a relapsing-remitting course and may lead to vision-threatening complications if untreated.

Causes

The exact cause is not fully understood, but it is believed to involve an autoimmune response targeting melanin-containing cells in the body. Genetic predisposition and environmental triggers (e.g., infections) may contribute to disease onset. The immune-mediated attack on melanocytes in the uvea, skin, and inner ear is thought to drive the clinical manifestations.

Risk Factors

• Genetic susceptibility (e.g., HLA associations)
• Ethnicity (more common in individuals of Asian, Hispanic, or Native American descent)
• Prior viral infections (e.g., herpesviruses)
• Female gender (slight predominance)

Symptoms

• Eye redness, pain, or photophobia (due to uveitis)
• Blurred vision or floaters
• Vitiligo (depigmented skin patches)
• Poliosis (whitening of eyebrows, eyelashes, or scalp hair)
• Tinnitus or hearing loss
• Headache or meningismus (in severe cases)

Diagnosis

Diagnosis is based on clinical presentation, including ocular findings (e.g., uveitis), extraocular manifestations (e.g., vitiligo, poliosis), and auditory symptoms. Ancillary tests may include ophthalmic examination, skin biopsy, and imaging to assess central nervous system involvement. Laboratory tests (e.g., HLA typing) may support the diagnosis but are not definitive.

Treatment Options

Treatment focuses on reducing inflammation and preventing complications. Corticosteroids (systemic or topical) are first-line therapy. Immunosuppressive agents (e.g., cyclosporine, azathioprine) may be used for refractory cases. Adjunctive therapies include phototherapy for skin depigmentation and hearing aids for auditory symptoms. Regular monitoring by an ophthalmologist is essential.

Prognosis and Follow-Up

Prognosis depends on disease severity and response to treatment. Early intervention can preserve vision, but relapses are common. Long-term follow-up with ophthalmology, dermatology, and otolaryngology is recommended to manage systemic manifestations and prevent complications.

Complications

• Permanent vision loss due to chronic uveitis or complications (e.g., cataracts, glaucoma)
• Progressive hearing loss
• Skin depigmentation (vitiligo) or poliosis
• Neurologic sequelae (e.g., meningitis, encephalitis)

Lifestyle & Prevention

• Avoid known triggers (e.g., infections, stress)
• Protect eyes from UV light
• Maintain regular follow-up with healthcare providers
• Manage comorbidities (e.g., autoimmune conditions)

When to Seek Professional Help

Seek immediate care for:

• Sudden vision changes or eye pain
• New or worsening skin depigmentation
• Persistent tinnitus or hearing loss
• Neurologic symptoms (e.g., headache, confusion)

Tips for Medical Coders

Document bilateral eye involvement clearly in clinical notes. Ensure specificity of ocular manifestations (e.g., uveitis type) and extraocular symptoms (e.g., vitiligo, poliosis) to support accurate coding. Use this code only when bilateral eye involvement is confirmed.